Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Nov 15, 2023 9:48am

228 Views

Post# 35736569

2 new target prices

Antibe Therapeutics (ATBPF)

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Antibe Therapeutics, with a price target of C$2.00. The company’s shares closed last Tuesday at $0.64.

Antibe Therapeutics (ATBPF)

Echelon Wealth Partners analyst Stefan Quenneville maintained a Buy rating on Antibe Therapeutics today and set a price target of C$2.00. The company’s shares closed last Monday at $0.66.

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions